Emitents | Olainfarm, AS (213800WCG52W62ENOP27) |
Veids | Finanšu pārskati |
Valoda | EN |
Statuss | Publicēts |
Versija | |
Datums | 2014-04-28 16:29:22 |
Versijas komentārs | |
Teksts |
Olaine, April 28, 2014
In 2013 Consolidated Sales
of Olainfarm Reached Almost 78 Million
Euro
Consolidated profit and loss
account of JSC Olainfarm for 2013 shows that the company has
reached sales of 77.9 million euro. This represents an increase by
4% compared to 2012, when sales of JSC Olainfarm were 75.2 million
euro.
After tax profit of the company in 2013 was 12.6 million euro,
which is a reduction by 9% compared to 2012, when the net profit
was 13.8 million euro.
During 2013 sales to all key markets of JSC Olainfarm continued
growing, except Ukraine, where due to extra shipments of 2012 they
shrank by 45%. The biggest sales increases were achieved in The
Netherlands, where products for WHO’s anti-tuberculosis products
are being sent. Sales there have increased by 351%.
Significant sales increase has also been achieved in Spain (sales
grew by 202%), Belarus (sales grew by 48%) and Uzbekistan (sales
grew by 42%). Major sales markets of JSC Olainfarm in 2013
were Russia, Latvia, Ukraine, Belarus, Kazakhstan and the
UK.
The bestselling products in 2013 were neurology medication
Neiromidin, Noofen and Adaptol, antibacterial medication Furamags
and cardiology medication Etacizīns.
During 2013 37 products have been registered in 7 different
countries, including the marketing partnership products.
Registration processes have been started also in Turkey, Mongolia,
Mexico and Kosovo. The work has been started at developing several
new final dosage forms, clinical trials of injectable form of
Kapikor (Olvazol) are being conducted.
With support of European Regional Development Fund
in 2013 laboratory equipment has been acquired which will allow
moving the production of nitrofuranes to a new production unit and
further improving production technologies of this group of
products.
In December 2013 Management Board of JSC Olainfarm adjusted
previously set profit and sales guidance. According to them the
sales of the Concern in 2013 were planned to be 75.1 million euro
while the net profit guidance was 12.5 million euro.
According to audited report the sales guidance has been
outperformed by 3.8%, while profit guidance was outperformed by
0.8%.
JSC Olainfarm is one of the
biggest pharmaceutical companies in Latvia with more than 40 years
of experience in production of medication and chemical and
pharmaceutical products. A basic principle of company's operations
is to produce reliable and effective top quality products for
Latvia and the rest of the world. Products made by the Group are
being exported to more than 35 countries of the world, including
the Baltics, Russia, other CIS, Europe, Asia, North America and
Australia.
Information
prepared by:
Salvis Lapiņš
Member of the Board
JSC Olainfarm
Mobile. +371 26 448 873
E-mail: slapinsh@olainfarm.lv |
Pielikumi |